Transplant International最新文献_第7页

Antibody-Mediated Rejection in Lung Transplantation: Diagnosis and Therapeutic Armamentarium in a 21st Century Perspective. 肺移植中抗体介导的排斥反应：21世纪视角下的诊断和治疗手段》。

IF 2.7 3区医学

Transplant International Pub Date : 2024-08-07 eCollection Date: 2024-01-01 DOI: 10.3389/ti.2024.12973

Jonathan Messika, Natalia Belousova, François Parquin, Antoine Roux

{"title":"Antibody-Mediated Rejection in Lung Transplantation: Diagnosis and Therapeutic Armamentarium in a 21st Century Perspective.","authors":"Jonathan Messika, Natalia Belousova, François Parquin, Antoine Roux","doi":"10.3389/ti.2024.12973","DOIUrl":"10.3389/ti.2024.12973","url":null,"abstract":"Humoral immunity is a major waypoint towards chronic allograft dysfunction in lung transplantation (LT) recipients. Though allo-immunization and antibody-mediated rejection (AMR) are well-known entities, some diagnostic gaps need to be addressed. Morphological analysis could be enhanced by digital pathology and artificial intelligence-based companion tools. Graft transcriptomics can help to identify graft failure phenotypes or endotypes. Donor-derived cell free DNA is being evaluated for graft-loss risk stratification and tailored surveillance. Preventative therapies should be tailored according to risk. The donor pool can be enlarged for candidates with HLA sensitization, with strategies combining plasma exchange, intravenous immunoglobulin and immune cell depletion, or with emerging or innovative therapies such as imlifidase or immunoadsorption. In cases of insufficient pre-transplant desensitization, the effects of antibodies on the allograft can be prevented by targeting the complement cascade, although evidence for this strategy in LT is limited. In LT recipients with a humoral response, strategies are combined, including depletion of immune cells (plasmapheresis or immunoadsorption), inhibition of immune pathways, or modulation of the inflammatory cascade, which can be achieved with photopheresis. Altogether, these innovative techniques offer promising perspectives for LT recipients and shape the 21st century's armamentarium against AMR.","PeriodicalId":23343,"journal":{"name":"Transplant International","volume":"37 ","pages":"12973"},"PeriodicalIF":2.7,"publicationDate":"2024-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11336419/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142018778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of Blood Pressure on Allograft Function and Survival in Kidney Transplant Recipients. 血压对肾移植受者异体移植功能和存活率的影响

IF 2.7 3区医学

Transplant International Pub Date : 2024-08-07 eCollection Date: 2024-01-01 DOI: 10.3389/ti.2024.12574

Hyo Jeong Kim, Kyung Won Kim, Young Su Joo, Junghwa Ryu, Hee-Yeon Jung, Kyung Hwan Jeong, Myung-Gyu Kim, Man Ki Ju, Seungyeup Han, Jong Soo Lee, Kyung Pyo Kang, Han Ro, Kyo Won Lee, Kyu Ha Huh, Myoung Soo Kim, Beom Seok Kim, Jaeseok Yang

{"title":"Impact of Blood Pressure on Allograft Function and Survival in Kidney Transplant Recipients.","authors":"Hyo Jeong Kim, Kyung Won Kim, Young Su Joo, Junghwa Ryu, Hee-Yeon Jung, Kyung Hwan Jeong, Myung-Gyu Kim, Man Ki Ju, Seungyeup Han, Jong Soo Lee, Kyung Pyo Kang, Han Ro, Kyo Won Lee, Kyu Ha Huh, Myoung Soo Kim, Beom Seok Kim, Jaeseok Yang","doi":"10.3389/ti.2024.12574","DOIUrl":"10.3389/ti.2024.12574","url":null,"abstract":"The optimal target blood pressure for kidney transplant (KT) patients remains unclear. We included 808 KT patients from the KNOW-KT as a discovery set, and 1,294 KT patients from the KOTRY as a validation set. The main exposures were baseline systolic blood pressure (SBP) at 1 year after KT and time-varying SBP. Patients were classified into five groups: SBP <110; 110-119; 120-129; 130-139; and ≥140 mmHg. SBP trajectories were classified into decreasing, stable, and increasing groups. Primary outcome was composite kidney outcome of ≥50% decrease in eGFR or death-censored graft loss. Compared with the 110-119 mmHg group, both the lowest (adjusted hazard ratio [aHR], 2.43) and the highest SBP (aHR, 2.25) were associated with a higher risk of composite kidney outcome. In time-varying model, also the lowest (aHR, 3.02) and the highest SBP (aHR, 3.60) were associated with a higher risk. In the trajectory model, an increasing SBP trajectory was associated with a higher risk than a stable SBP trajectory (aHR, 2.26). This associations were consistent in the validation set. In conclusion, SBP ≥140 mmHg and an increasing SBP trajectory were associated with a higher risk of allograft dysfunction and failure in KT patients.","PeriodicalId":23343,"journal":{"name":"Transplant International","volume":"37 ","pages":"12574"},"PeriodicalIF":2.7,"publicationDate":"2024-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11336573/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142018779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Accessibility of Percutaneous Biopsy in Retrocolic-Placed Pancreatic Grafts With a Duodeno-Duodenostomy. 带十二指肠造口的网结扎胰腺移植物经皮活检的可及性

IF 2.7 3区医学

Transplant International Pub Date : 2024-08-06 eCollection Date: 2024-01-01 DOI: 10.3389/ti.2024.12682

Clara Bassaganyas, Anna Darnell, Alexandre Soler-Perromat, Gerard Rafart, Pedro Ventura-Aguiar, Miriam Cuatrecasas, Joana Ferrer-Fàbrega, Carmen Ayuso, Ángeles García-Criado

{"title":"Accessibility of Percutaneous Biopsy in Retrocolic-Placed Pancreatic Grafts With a Duodeno-Duodenostomy.","authors":"Clara Bassaganyas, Anna Darnell, Alexandre Soler-Perromat, Gerard Rafart, Pedro Ventura-Aguiar, Miriam Cuatrecasas, Joana Ferrer-Fàbrega, Carmen Ayuso, Ángeles García-Criado","doi":"10.3389/ti.2024.12682","DOIUrl":"10.3389/ti.2024.12682","url":null,"abstract":"Duodeno-duodenostomy (DD) has been proposed as a more physiological alternative to conventional duodeno-jejunostomy (DJ) for pancreas transplantation. Accessibility of percutaneous biopsies in these grafts has not yet been assessed. We conducted a retrospective study including all pancreatic percutaneous graft biopsies requested between November 2009 and July 2021. Whenever possible, biopsies were performed under ultrasound (US) guidance or computed tomography (CT) guidance when the US approach failed. Patients were classified into two groups according to surgical technique (DJ and DD). Accessibility, success for histological diagnosis and complications were compared. Biopsy was performed in 93/136 (68.4%) patients in the DJ group and 116/132 (87.9%) of the DD group (p = 0.0001). The graft was not accessible for biopsy mainly due to intestinal loop interposition (n = 29 DJ, n = 10 DD). Adequate sample for histological diagnosis was obtained in 86/93 (92.5%) of the DJ group and 102/116 (87.9%) of the DD group (p = 0.2777). One minor complication was noted in the DD group. The retrocolic position of the DD pancreatic graft does not limit access to percutaneous biopsy. This is a safe technique with a high histological diagnostic success rate.","PeriodicalId":23343,"journal":{"name":"Transplant International","volume":"37 ","pages":"12682"},"PeriodicalIF":2.7,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11333234/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142009524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prophylactic Peri-Nephric Drain Placement in Renal Transplant Surgery: A Systematic Review and Meta-Analysis. 肾移植手术中预防性肾周引流管置入：系统综述与元分析》。

IF 2.7 3区医学

Transplant International Pub Date : 2024-08-02 eCollection Date: 2024-01-01 DOI: 10.3389/ti.2024.13030

Adil S Lakha, Shahzaib Ahmed, James Hunter, John O'Callaghan

{"title":"Prophylactic Peri-Nephric Drain Placement in Renal Transplant Surgery: A Systematic Review and Meta-Analysis.","authors":"Adil S Lakha, Shahzaib Ahmed, James Hunter, John O'Callaghan","doi":"10.3389/ti.2024.13030","DOIUrl":"10.3389/ti.2024.13030","url":null,"abstract":"Renal transplantation is common worldwide, with >25,000 procedures performed in 2022. Usage of prophylactic perinephric drains is variable in renal transplantation; drains are associated with risks, and there is a lack of consensus regarding benefit of routine drain placement in these patients. This meta-analysis assessed whether prophylactic drainage reduced need for reintervention postoperatively. This systematic review and meta-analysis was carried out using the Preferred Reporting Items in Systematic Reviews and Meta-Analysis, and prospectively registered on PROSPERO. Summary statistics for outcomes of interest underwent meta-analyses to a confidence interval (CI) of 95% and are presented as Forest Plots for Odds Ratio (OR). A systematic literature search in June 2023 revealed 1,540 unique articles across four databases. Of these, four retrospective cohort studies were selected. Meta-analysis of three studies showed no significant reduction in reintervention rate with pre-emptive drain placement, OR = 0.59 (95% CI: 0.16-2.23), p = 0.44. Meta-analysis did not show a significant reduction in perinephric collections with prophylactic drain insertion OR = 0.55 (95% CI: 0.13-2.37), p = 0.42. Finally, there is not good evidence that drain placement reduces superficial wound complications or improves 12-month graft survival. Further work is needed, including well-designed, prospective studies to assess the risks and benefits of drain placement in these patients. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023422685, Identifier PROSPERO CRD42021255795.","PeriodicalId":23343,"journal":{"name":"Transplant International","volume":"37 ","pages":"13030"},"PeriodicalIF":2.7,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11327091/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142000743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Donor-Derived Cell-Free DNA as a Companion Biomarker for AMR Treatment With Daratumumab: Case Series. 作为达拉单抗治疗急性髓系白血病的辅助生物标记物的供体来源细胞游离 DNA：病例系列。

IF 2.7 3区医学

Transplant International Pub Date : 2024-08-01 eCollection Date: 2024-01-01 DOI: 10.3389/ti.2024.13213

Bilgin Osmanodja, Aylin Akifova, Klemens Budde, Michael Oellerich, Julia Beck, Kirsten Bornemann-Kolatzki, Ekkehard Schütz, Joachim Velden, Claudia Lehmann, Bastian Malte Krüger, Anette Bachmann, Jan Kowald

{"title":"Donor-Derived Cell-Free DNA as a Companion Biomarker for AMR Treatment With Daratumumab: Case Series.","authors":"Bilgin Osmanodja, Aylin Akifova, Klemens Budde, Michael Oellerich, Julia Beck, Kirsten Bornemann-Kolatzki, Ekkehard Schütz, Joachim Velden, Claudia Lehmann, Bastian Malte Krüger, Anette Bachmann, Jan Kowald","doi":"10.3389/ti.2024.13213","DOIUrl":"10.3389/ti.2024.13213","url":null,"abstract":"Antibody-mediated rejection (AMR) is among the most frequent causes for graft loss after kidney transplantation. While there are no approved therapies, several case reports with daratumumab and the very recent phase 2 trial of felzartamab in AMR have indicated the potential efficacy of therapeutic interventions targeting CD38. Donor-derived cell-free DNA (dd-cfDNA) is an emerging biomarker with injury-specific release and a short half-life, which could facilitate early diagnosis of AMR and monitoring of treatment response. We describe two cases of patients with chronic active AMR, who were treated with monthly daratumumab infusions, and in whom donor-derived cell-free DNA (dd-cfDNA) was measured longitudinally to monitor treatment response. In both patients, daratumumab treatment led to stabilization of kidney function parameters, a strong decline of dd-cfDNA below the previously established threshold for rejection, and partial or complete histologic resolution of AMR activity. Our case series suggests that dd-cfDNA may be a useful companion biomarker for longitudinal monitoring of anti-CD38 treatment in patients with AMR.","PeriodicalId":23343,"journal":{"name":"Transplant International","volume":"37 ","pages":"13213"},"PeriodicalIF":2.7,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11325154/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141988913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Orthostatic Ex-Vivo Lung Perfusion (EVLP): A Proof of Concept. 体外肺灌注（EVLP）：概念验证

IF 2.7 3区医学

Transplant International Pub Date : 2024-07-31 eCollection Date: 2024-01-01 DOI: 10.3389/ti.2024.13178

Massimo Boffini, Andrea Costamagna, Matteo Marro, Erika Simonato, Paola Cassoni, Luca Bertero, Vito Fanelli, Cristina Barbero, Luca Brazzi, Mauro Rinaldi

引用次数: 0

Transplant Trial Watch. 移植试验观察。

IF 2.7 3区医学

Transplant International Pub Date : 2024-07-22 eCollection Date: 2024-01-01 DOI: 10.3389/ti.2024.13457

John M O'Callaghan, Simon Knight, John Fallon

引用次数: 0

Is Night Surgery a Nightmare for Lung Transplantation? 夜间手术是肺移植的噩梦吗？

IF 2.7 3区医学

Transplant International Pub Date : 2024-07-02 eCollection Date: 2024-01-01 DOI: 10.3389/ti.2024.12816

Sébastien Tanaka, Christian De Tymowski, Erevan Dupuis, Alexy Tran-Dinh, Brice Lortat-Jacob, Adela Harpan, Sylvain Jean-Baptiste, Sandrine Boudinet, Chahra-Zad Tahri, Mathilde Salpin, Yves Castier, Pierre Mordant, Hervé Mal, Antoine Girault, Enora Atchade, Philippe Montravers

{"title":"Is Night Surgery a Nightmare for Lung Transplantation?","authors":"Sébastien Tanaka, Christian De Tymowski, Erevan Dupuis, Alexy Tran-Dinh, Brice Lortat-Jacob, Adela Harpan, Sylvain Jean-Baptiste, Sandrine Boudinet, Chahra-Zad Tahri, Mathilde Salpin, Yves Castier, Pierre Mordant, Hervé Mal, Antoine Girault, Enora Atchade, Philippe Montravers","doi":"10.3389/ti.2024.12816","DOIUrl":"10.3389/ti.2024.12816","url":null,"abstract":"Night work is frequently associated with sleep deprivation and is associated with greater surgical and medical complications. Lung transplantation (LT) is carried out both at night and during the day and involves many medical healthcare workers. The goal of the study was to compare morbidity and mortality between LT recipients according to LT operative time. We performed a retrospective, observational, single-center study. When the procedure started between 6 AM and 6 PM, the patient was allocated to the Daytime group. If the procedure started between 6 PM and 6 AM, the patient was allocated to the Nighttime group. Between January 2015 and December 2020, 253 patients were included. A total of 168 (66%) patients were classified into the Day group, and 85 (34%) patients were classified into the Night group. Lung Donors' general characteristics were similar between the groups. The 90-day and one-year mortality rates were similar between the groups (90-days: n = 13 (15%) vs. n = 26 (15%), p = 0.970; 1 year: n = 18 (21%) vs. n = 42 (25%), p = 0.499). Daytime LT was associated with more one-year airway dehiscence (n = 36 (21%) vs. n = 6 (7.1%), p = 0.004). In conclusion, among patients who underwent LT, there was no significant association between operative time and survival.","PeriodicalId":23343,"journal":{"name":"Transplant International","volume":"37 ","pages":"12816"},"PeriodicalIF":2.7,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11250068/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141627769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Potential Role of the Leucocyte Immunoglobulin-Like Receptors in Kidney Transplant Rejection: A Mini Review. 白细胞免疫球蛋白样受体在肾移植排斥反应中的潜在作用：微型综述。

IF 2.7 3区医学

Transplant International Pub Date : 2024-07-01 eCollection Date: 2024-01-01 DOI: 10.3389/ti.2024.12995

Jovanne Palvair, Imane Farhat, Mélanie Chaintreuil, Ludivine Dal Zuffo, Lennie Messager, Claire Tinel, Baptiste Lamarthée

{"title":"The Potential Role of the Leucocyte Immunoglobulin-Like Receptors in Kidney Transplant Rejection: A Mini Review.","authors":"Jovanne Palvair, Imane Farhat, Mélanie Chaintreuil, Ludivine Dal Zuffo, Lennie Messager, Claire Tinel, Baptiste Lamarthée","doi":"10.3389/ti.2024.12995","DOIUrl":"10.3389/ti.2024.12995","url":null,"abstract":"Antibody-mediated rejection (ABMR) remains one of the main causes of long-term graft failure after kidney transplantation, despite the development of powerful immunosuppressive therapy. A detailed understanding of the complex interaction between recipient-derived immune cells and the allograft is therefore essential. Until recently, ABMR mechanisms were thought to be solely caused by adaptive immunity, namely, by anti-human leucocyte antigen (HLA) donor-specific antibody. However recent reports support other and/or additive mechanisms, designating monocytes/macrophages as innate immune contributors of ABMR histological lesions. In particular, in mouse models of experimental allograft rejection, monocytes/macrophages are readily able to discriminate non-self via paired immunoglobulin receptors (PIRs) and thus accelerate rejection. The human orthologs of PIRs are leukocyte immunoglobulin-like receptors (LILRs). Among those, LILRB3 has recently been reported as a potential binder of HLA class I molecules, shedding new light on LILRB3 potential as a myeloid mediator of allograft rejection. In this issue, we review the current data on the role of LILRB3 and discuss the potential mechanisms of its biological functions.","PeriodicalId":23343,"journal":{"name":"Transplant International","volume":"37 ","pages":"12995"},"PeriodicalIF":2.7,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11247310/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141621004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Transjugular Intrahepatic Portosystemic Shunt Is Associated With Better Waitlist Management of Liver Transplant Candidates With Hepatocellular Carcinoma. 经颈静脉肝内门体分流术与肝细胞癌肝移植候选者更好的候选管理有关。

IF 2.7 3区医学

Transplant International Pub Date : 2024-06-26 eCollection Date: 2024-01-01 DOI: 10.3389/ti.2024.12781

Sofia El Hajji, Stéphanie Lacotte, Beat Moeckli, François Cauchy, Philippe Compagnon, Christian Toso

{"title":"Transjugular Intrahepatic Portosystemic Shunt Is Associated With Better Waitlist Management of Liver Transplant Candidates With Hepatocellular Carcinoma.","authors":"Sofia El Hajji, Stéphanie Lacotte, Beat Moeckli, François Cauchy, Philippe Compagnon, Christian Toso","doi":"10.3389/ti.2024.12781","DOIUrl":"10.3389/ti.2024.12781","url":null,"abstract":"Transjugular intrahepatic portosystemic shunt (TIPS) reduces portal hypertension complications. Its impact on hepatocellular carcinoma (HCC) remains unclear. We evaluated 42,843 liver transplant candidates with HCC from the Scientific Registry of Transplant Recipients (2002-2022). 4,484 patients with and without TIPS were propensity score-matched 1:3. Analysing wait-list changes in total tumor volume, HCC count, and alpha-fetoprotein levels, and assessing survival from listing and transplantation; TIPS correlated with a decreased nodule count (-0.24 vs. 0.04, p = 0.028) over a median wait period of 284 days (IQR 195-493) and better overall survival from listing (95.6% vs. 91.5% at 1 year, p < 0.0001). It was not associated with changes in tumor volume (0.28 vs. 0.11 cm³/month, p = 0.58) and AFP (14.37 vs. 20.67 ng/mL, p = 0.42). Post-transplant survival rates (91.8% vs. 91.7% at 1 year, p = 0.25) and HCC recurrence (5.1% vs. 5.9% at 5 years, p = 0.14) were similar, with a median follow-up of 4.98 years (IQR 2.5-8.08). While TIPS was associated with a reduced nodule count and improved waitlist survival, it did not significantly impact HCC growth or aggressiveness. These findings suggest potential benefits of TIPS in HCC management, but further studies need to confirm TIPS safety.","PeriodicalId":23343,"journal":{"name":"Transplant International","volume":"37 ","pages":"12781"},"PeriodicalIF":2.7,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11265282/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141752929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0